Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 194

1.

Involvement of IGF-1R regulation by miR-515-5p modifies breast cancer risk among BRCA1 carriers.

Gilam A, Edry L, Mamluk-Morag E, Bar-Ilan D, Avivi C, Golan D, Laitman Y, Barshack I, Friedman E, Shomron N.

Breast Cancer Res Treat. 2013 Apr;138(3):753-60. doi: 10.1007/s10549-013-2502-5. Epub 2013 Apr 3.

PMID:
23549953
2.

A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers.

Kadouri L, Kote-Jarai Z, Hubert A, Durocher F, Abeliovich D, Glaser B, Hamburger T, Eeles RA, Peretz T.

Br J Cancer. 2004 May 17;90(10):2002-5.

3.

A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers.

Levy-Lahad E, Lahad A, Eisenberg S, Dagan E, Paperna T, Kasinetz L, Catane R, Kaufman B, Beller U, Renbaum P, Gershoni-Baruch R.

Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3232-6.

4.

The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.

Satagopan JM, Offit K, Foulkes W, Robson ME, Wacholder S, Eng CM, Karp SE, Begg CB.

Cancer Epidemiol Biomarkers Prev. 2001 May;10(5):467-73.

5.

Genetic variation in IGF-1 and breast cancer risk in Ashkenazi carriers and noncarriers of BRCA1/2 mutations.

Khoury-Shakour S, Lejbkowicz F, Barnett-Griness O, Tamir A, Pinchev M, Rennert G.

Eur J Cancer Prev. 2009 Sep;18(5):361-7. doi: 10.1097/CEJ.0b013e32832e0942.

PMID:
19543094
6.
7.

Identification of fifteen novel germline variants in the BRCA1 3'UTR reveals a variant in a breast cancer case that introduces a functional miR-103 target site.

Brewster BL, Rossiello F, French JD, Edwards SL, Wong M, Wronski A, Whiley P, Waddell N, Chen X, Bove B; kConFab, Hopper JL, John EM, Andrulis I, Daly M, Volorio S, Bernard L, Peissel B, Manoukian S, Barile M, Pizzamiglio S, Verderio P, Spurdle AB, Radice P, Godwin AK, Southey MC, Brown MA, Peterlongo P.

Hum Mutat. 2012 Dec;33(12):1665-75. doi: 10.1002/humu.22159. Epub 2012 Aug 2.

PMID:
22753153
8.

miR-485-5p binding site SNP rs8752 in HPGD gene is associated with breast cancer risk.

He N, Zheng H, Li P, Zhao Y, Zhang W, Song F, Chen K.

PLoS One. 2014 Jul 8;9(7):e102093. doi: 10.1371/journal.pone.0102093. eCollection 2014.

9.

Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation.

Bernholtz S, Laitman Y, Kaufman B, Paluch Shimon S, Friedman E.

Breast Cancer Res Treat. 2011 Sep;129(2):557-63. doi: 10.1007/s10549-011-1509-z. Epub 2011 Apr 16.

PMID:
21499684
10.

Single-nucleotide polymorphisms in the p53 pathway genes modify cancer risk in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent.

Yarden RI, Friedman E, Metsuyanim S, Olender T, Ben-Asher E, Papa MZ.

Mol Carcinog. 2010 Jun;49(6):545-55. doi: 10.1002/mc.20618.

PMID:
20306497
11.

CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers.

Kadouri L, Easton DF, Edwards S, Hubert A, Kote-Jarai Z, Glaser B, Durocher F, Abeliovich D, Peretz T, Eeles RA.

Br J Cancer. 2001 Jul 6;85(1):36-40.

12.

The deoxycholic acid targets miRNA-dependent CAC1 gene expression in multidrug resistance of human colorectal cancer.

Kong Y, Bai PS, Sun H, Nan KJ, Chen NZ, Qi XG.

Int J Biochem Cell Biol. 2012 Dec;44(12):2321-32. doi: 10.1016/j.biocel.2012.08.006. Epub 2012 Aug 10.

PMID:
22903020
13.

An miR-502-binding site single-nucleotide polymorphism in the 3'-untranslated region of the SET8 gene is associated with early age of breast cancer onset.

Song F, Zheng H, Liu B, Wei S, Dai H, Zhang L, Calin GA, Hao X, Wei Q, Zhang W, Chen K.

Clin Cancer Res. 2009 Oct 1;15(19):6292-300. doi: 10.1158/1078-0432.CCR-09-0826. Epub 2009 Sep 29.

14.

Regulation of the MIR155 host gene in physiological and pathological processes.

Elton TS, Selemon H, Elton SM, Parinandi NL.

Gene. 2013 Dec 10;532(1):1-12. doi: 10.1016/j.gene.2012.12.009. Epub 2012 Dec 14. Review.

PMID:
23246696
15.

Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility.

Nicoloso MS, Sun H, Spizzo R, Kim H, Wickramasinghe P, Shimizu M, Wojcik SE, Ferdin J, Kunej T, Xiao L, Manoukian S, Secreto G, Ravagnani F, Wang X, Radice P, Croce CM, Davuluri RV, Calin GA.

Cancer Res. 2010 Apr 1;70(7):2789-98. doi: 10.1158/0008-5472.CAN-09-3541. Epub 2010 Mar 23.

16.

Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin.

Wolf I, Laitman Y, Rubinek T, Abramovitz L, Novikov I, Beeri R, Kuro-O M, Koeffler HP, Catane R, Freedman LS, Levy-Lahad E, Karlan BY, Friedman E, Kaufman B.

Oncogene. 2010 Jan 7;29(1):26-33. doi: 10.1038/onc.2009.301. Epub 2009 Oct 5.

PMID:
19802015
17.

Intratumoral IGF-I protein expression is selectively upregulated in breast cancer patients with BRCA1/2 mutations.

Hudelist G, Wagner T, Rosner M, Fink-Retter A, Gschwantler-Kaulich D, Czerwenka K, Kroiss R, Tea M, Pischinger K, Köstler WJ, Attems J, Mueller R, Blaukopf C, Kubista E, Hengstschläger M, Singer CF.

Endocr Relat Cancer. 2007 Dec;14(4):1053-62.

18.

Elevated insulin-like growth factor-I receptor (IGF-IR) levels in primary breast tumors associated with BRCA1 mutations.

Maor S, Yosepovich A, Papa MZ, Yarden RI, Mayer D, Friedman E, Werner H.

Cancer Lett. 2007 Nov 18;257(2):236-43. Epub 2007 Sep 4.

PMID:
17766039
19.

Single nucleotide polymorphisms in miRNA binding sites and miRNA genes as breast/ovarian cancer risk modifiers in Jewish high-risk women.

Kontorovich T, Levy A, Korostishevsky M, Nir U, Friedman E.

Int J Cancer. 2010 Aug 1;127(3):589-97. doi: 10.1002/ijc.25065.

20.

Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.

Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, Offit K.

Clin Cancer Res. 2002 Dec;8(12):3776-81.

Supplemental Content

Support Center